Acute activation of metabolic syndrome components in pediatric acute lymphoblastic leukemia patients treated with dexamethasone

Lidewij T. Warris*, Erica L T Van Den Akker, Marc B. Bierings, Cor Den Van Bos, Christian M. Zwaan, Sebastiaan D T Sassen, Wim J E Tissing, Margreet A. Veening, Rob Pieters, Marry M. Van Den Heuvel-Eibrink

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects. Because studies regarding the effects of dexamethasone are limited by their small scale, we prospectively studied the direct effects of treating pediatric ALL with dexamethasone administration with respect to activation of components of metabolic syndrome (MetS); in addition, we investigated whether these side effects were correlated with the level of dexamethasone. Fifty pediatric patients (3-16 years of age) with ALL were studied during a 5-day dexamethasone course during the maintenance phase of the Dutch Childhood Oncology Group ALL-10 and ALL-11 protocols. Fasting insulin, glucose, total cholesterol, HDL, LDL, and triglycerides levels were measured at baseline (before the start of dexamethasone; T1) and on the fifth day of treatment (T2). Dexamethasone trough levels were measured at T2. We found that dexamethasone treatment significantly increased the following fasting serum levels (P3.4) from 8% to 85% (P

Original languageEnglish
Article numbere0158225
JournalPLoS ONE [E]
Volume11
Issue number6
DOIs
Publication statusPublished - 1 Jun 2016

Fingerprint

Dive into the research topics of 'Acute activation of metabolic syndrome components in pediatric acute lymphoblastic leukemia patients treated with dexamethasone'. Together they form a unique fingerprint.

Cite this